No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration; no secondary primary lung cancer diagnosed concurrently or within 2 years prior to registration
Participants must have histologically or cytologically confirmed breast cancer, with diagnosed or suspected metastatic, inoperable locally advanced breast cancer, or inoperable locally recurrent breast cancer for which standard curative or palliative measures do not exist or are no longer effective
Locally advanced or metastatic HER2-positive breast cancer that has relapsed or is refractory to established therapies
Prior chemotherapy or any other investigational agents for the treatment of locally advanced or metastatic pancreatic cancer
Progressive metastatic or locally advanced or metastatic breast cancer.
Relapsed, locally-advanced or metastatic colorectal or pancreatic cancer, squamous NSCLC, or SCCHN patients who are not candidates for standard therapy.
Any breast cancer patient with metastatic or locally recurrent unresectable breast cancer currently progressive, after at least two prior lines of therapy in the advanced setting; patients with HER2+ disease must have failed two or more different anti-HER2 agents
Pathologically confirmed diagnosis of breast cancer with radiographic evidence of incurable, unresectable, locally advanced or metastatic disease (LA/MBC)
Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment
Sign of locally advanced disease or metastatic bladder cancer
Diagnosed with (a) locally advanced or metastatic (stage III-IV) breast cancer or (b) advanced prostate cancer
Biopsy proven locally advanced or metastatic prostate cancer.
Locally advanced/non-operable or metastatic breast cancer that has not been previously treated in the metastatic setting with systemic therapy (i.e. first line treatment)
Histologic proof of metastatic or locally advanced, unresectable breast cancer
Received >2 prior systemic anti-cancer drug regimen for locally advanced disease
Non-hepatocellular carcinoma subjects must have received at least 1 prior standard of care systemic anti-cancer therapy for their locally advanced or metastatic disease.
Metastatic or locally advanced breast cancer for which endocrine therapy is an appropriate treatment option
Locally advanced or metastatic breast cancer
Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes
Locally advanced or metastatic breast cancer
Histologically or cytologically confirmed breast cancer that is either locally advanced or metastatic. Locally advanced breast cancer must not be amenable to surgical resection or radiation with curative intent.
Locally advanced, relapsed, and/or metastatic cancer
Phase I (Cohorts E and F): Post-menopausal females with locally advanced or metastatic hormone receptor-positive breast cancer that has progressed or failed to respond to at least one prior endocrine therapy in the adjuvant or metastatic setting
Phase II: Post-menopausal female participants with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer
Have not previously received therapy for the treatment of unresectable locally-advanced breast cancer or metastatic breast cancer
Previous chemotherapy for locally advanced or metastatic gastric cancer.
Adult women (? 18 years of age) with metastatic or locally advanced breast cancer
Progression while on, or within one month of end of letrozole or anastrozole treatment for locally advanced or metastatic breast cancer.
Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy.
Locally advanced unresectable pancreatic cancer by National Comprehensive Cancer Network (NCCN) criteria
Patients may have received up to one prior line of chemotherapy for metastatic or unresectable locally advanced breast cancer
Prior treatment with any systemic anti-cancer therapy for locally advanced/metastatic NSCLC.
Patients whose esophageal or GEJ cancer has become metastatic or unresectable locally advanced within 6 months of completing definitive therapy for localized or locally advanced cancer can be considered as having received one line of therapy for advanced cancer
Willing and able to consent for biopsy of locally-advanced or metastatic breast cancer prior to treatment
Metastatic or locally advanced unresectable breast cancer (includes metastatic or locally advanced unresectable breast cancer which is diagnosed while on adjuvant letrozole or exemestane)
Subjects must have metastatic or locally advanced, unresectable cancer; cancer must be “active” (i.e. demonstrable by physical examination, blood tests, or radiographical procedures)
Patients must not have received any prior systemic therapy for metastatic or locally advanced colorectal cancer (CRC); prior VEGF inhibitors are not allowed
Patients with clinical evidence of locally advanced, nodal, or metastatic bladder cancer
Patients whose tumors are defined as locally advanced cancer or metastatic cancer are not eligible
Patients may have received up to one prior line of chemotherapy for metastatic or unresectable locally advanced breast cancer
Participants with HER2-positive and hormone receptor-positive advanced metastatic or locally advanced breast cancer
Previous systemic non-hormonal anticancer therapy in the metastatic or locally advanced breast cancer setting
Locally advanced/unresectable or metastatic breast cancer
Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment
Patients must show signs of progression during or =< 4 months after being treated with a first line therapy for their metastatic or locally advanced inoperable cancer
Diagnosis of locally advanced or metastatic liver cancer obtained by histology/cytology or by imaging
Locally advanced or inflammatory breast cancer (stage IIIA to IIIC)
Subjects with histologically confirmed advanced primary endometrial cancer (locally advanced and incurable endometrial cancer that has been treated with surgery and/or radiation or is ineligible for such treatment), or recurrent or metastatic endometrial cancer, and
No more than four prior systemic therapies for locally advanced or metastatic cancer
Locally advanced or inflammatory cervical or uterine cancer
Prior systemic therapy for locally advanced or metastatic hepatocellular cancer
Histological documentation of incurable, locally advanced, or metastatic non-squamous
Metastatic or unresectable locally advanced/recurrent breast cancer
Patients must have histologically confirmed breast cancer that is:\r\n* Metastatic; OR\r\n* Incurable and locally advanced, as determined by the treating physician
Breast cancer that is locally advanced or metastatic
Patients with confirmed HER-2 positive, metastatic or non-operable locally advanced breast or gastric cancer
Previous systemic non-hormonal anti-cancer therapy in the metastatic or locally advanced breast cancer setting
Postmenopausal women with HER2-, HR+ locally advanced or metastatic breast cancer
Previous chemotherapy for locally advanced or metastatic breast cancer
Histologic documentation of incurable, locally advanced or metastatic disease that has failed prior chemotherapy and for which no standard therapy exists, including the following: non-squamous NSCLC or non-mucinous and platinum-resistant ovarian cancer
Patients must have progressed during or after at least one previous systemic, anti-cancer treatment for locally advanced or metastatic NSCLC.
Locally advanced, recurrent, or metastatic, PIK3CA mutant, incurable solid tumor malignancy, including breast cancer Stages I and II, Arm B:
Postmenopausal female participants with histologically documented locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast cancer
Postmenopausal female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2? breast cancer Stages I and II:
Patient is at least 3 weeks post-diagnosis of an incurable (locally advanced or metastatic) solid malignancy
PATIENTS: Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)
Patients with advanced cancer (locally advanced, metastatic, recurrent and/or incurable cancer)
Patients with diagnosis of advanced cancer, including recurrent, locally advanced, or metastatic cancer
Diagnosis of advanced cancer (defined as locally advanced, metastatic, recurrent, or incurable disease)
Locally advanced breast cancer patients treated with surgery and adjuvant radiation
No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration; no secondary primary lung cancer diagnosed concurrently or within 2 year prior to registration
Locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant chemotherapy
Advanced cancer diagnosis (locally advanced, recurrent or metastatic disease)
Patients with a diagnosis of advanced cancer, including recurrent, locally advanced, or metastatic cancer
Patients with the diagnosis of advanced cancer defined as locally advanced, recurrent or metastatic disease
Diagnosis of advanced cancer, defined as locally advanced, recurrent or metastatic disease
Locally advanced or metastatic head and neck cancer.
Participants must have metastatic or locally advanced incurable anal cancer that has been histologically confirmed; patients with locally advanced anal cancer must have had cancer recurrence after chemoradiation and must be unresectable